Potential Biomarkers in Atrial Fibrillation: Insight Into Their Clinical Significance
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Lippincott Williams and Wilkins
Abstract
In risk-stratifying patients with atrial fibrillation (AF), physicians rely heavily on clinical parameters that provide risk scores and determine treatment strategies. There has been increasing research on potential biomarkers in the blood that could more accurately determine both risk of complications in AF and risk of incidence of AF. This review highlights the clinical significance of 5 novel biomarkers that have been shown to be linked to AF. These biomarkers are carbohydrate antigen 125, galectin-3, growth differentiation factor-15, a member of the interleukin 1 receptor family, IL1RL1 (ST2), and N-terminal pro B-type natriuretic peptide. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Description
Keywords
Atrial fibrillation, Biomarker, Carbohydrate antigen 125, Galectin-3, Growth differentiation factor-15, N-terminal pro b-type natriuretic peptide, Suppression of tumorigenicity 2, Action potentials, Animals, Atrial function, Biomarkers, Blood proteins, Ca-125 antigen, Clinical decision-making, Galectins, Growth differentiation factor 15, Heart atria, Heart rate, Humans, Membrane proteins, Natriuretic peptide, brain, Peptide fragments, Predictive value of tests, Prognosis, Receptors, interleukin-1 type i, Biological marker, Brain natriuretic peptide, Ca 125 antigen, Galectin, Gdf15 protein, human, Il1r1 protein, human, Interleukin 1 receptor type i, Lgals3 protein, human, Membrane protein, Muc16 protein, human, Peptide fragment, Plasma protein, Pro-brain natriuretic peptide (1-76), Action potential, Animal, Blood, Clinical decision making, Heart atrium, Heart atrium function, Human, Metabolism, Pathophysiology, Predictive value